BioCryst’s persistence for patient insights leads to a bigger market for HAE drug Orladeyo
Sometimes finding out how patients really feel about treatment takes persistence. That’s what BioCryst Pharmaceuticals learned when it started talking to patients about its new oral preventative treatment for hereditary angioedema. Two years ago, after pivotal trial results came in for the drug that would become Orladeyo, BioCryst had just begun its market research with a study… Read More »